AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer

Lynparza has been designed to exploit DNA damage response (DDR) pathway deficiencies, like the BRCA mutations, to preferentially eliminate cancer cells. Especially, in vitro studies have demonstrated that